Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

RECOMMENDED

Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Lancet Neurol.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N

doi: 10.1016/S1474-4422(19)30151-6.

RECOMMENDED

Multiple Sclerosis

Paediatric multiple sclerosis: a new era in diagnosis and treatment

Dev Med Child Neurol.

Duignan S, Brownlee W, Wassmer E, Hemingway C, Lim M, Ciccarelli O, Hacohen Y

doi: 10.1111/dmcn.

Multiple Sclerosis

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Mult Scler.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F

doi: 10.1177/1352458517751049.

COMMENTED

Multiple Sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Mult Scler J Exp Transl Clin.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR)

doi: 10.1177/2055217318814562.

Multiple Sclerosis

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Nat Rev Neurol.

Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R

doi: 10.1038/nrneurol.2017.81.

Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain.

Correale J, Gaitán MI, Ysrraelit MC, Fiol MP

doi: 10.1093/brain/aww258.

COMMENTED

Multiple Sclerosis

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research

BMC Neurol.

Steinemann N, Kuhle J, Calabrese P, Kesselring J, Disanto G, Merkler D, Pot C, Ajdacic-Gross V, Rodgers S, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry

doi: 10.1186/s12883-018-1118-0.

Related content

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Paediatric multiple sclerosis: a new era in diagnosis and treatment

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research